Prosecution Insights
Last updated: November 19, 2026
Application No. 18/569,714

USE OF MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE

Non-Final OA §102§OTHER
Filed
Dec 13, 2023
Priority
Jun 14, 2021 — CU 2021-0046 +1 more
Examiner
PAK, MICHAEL D
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Centro De Inmunología Molecular
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
417 granted / 712 resolved
-1.4% vs TC avg
Strong +30% interview lift
Without
With
+30.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
20 currently pending
Career history
737
Total Applications
across all art units

Statute-Specific Performance

§101
7.9%
-32.1% vs TC avg
§103
22.1%
-17.9% vs TC avg
§102
21.7%
-18.3% vs TC avg
§112
36.5%
-3.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 712 resolved cases

Office Action

§102 §OTHER
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Preliminary Claims filed July 9, 2024 are entered. Claims 6-12 are pending. Claims 1-5 are canceled. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 6-12 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Wei et al. (US 2014/0170159). Wei teach the treatment of hypoxemia, respiratory insufficiency/failure and ARDS (para 151, 826) by administering anti-EGFR (para 7, 807, 826) intravenously or subcutaneously (para 158, 781, 867) at 1 mg/kg (para 161, 860). Wei teach the anti-EGFR antibodies such as cetuximab, nimotuzumab and panitumumab (para 7, 406, 624). Wei teach the multiple doses of pharmaceutical composition comprising the antibody and optimization of the doses; and treatment over several day including initial and maintenance dose; two or more doses separated by 3 days (which is 72 hours) (para 791, 859, 861, 863). Wei teach the diseases are caused by viruses, bacteria and fungi including Epstein Barr, S. Pneumonia and Aspergillus (para 828). No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL D PAK whose telephone number is (571)272-0879. The examiner can normally be reached on flexible time. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached on 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL D PAK/Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Dec 13, 2023
Application Filed
Nov 02, 2026
Non-Final Rejection mailed — §102, §OTHER (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12791568
TREATMENT AND DIAGNOSIS OF CHRONIC INFLAMMATORY CONDITIONS IN THE LOWER URINARY TRACT
4y 11m to grant Granted Nov 10, 2026
Patent 12773450
CORONAVIRUS VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO
4y 0m to grant Granted Oct 27, 2026
Patent 12760063
ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY
4y 5m to grant Granted Oct 13, 2026
Patent 12714738
METHODS AND AGENTS FOR TREATING ACUTE NEUROINFLAMMATORY INJURY
4y 7m to grant Granted Aug 25, 2026
Patent 12709637
REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS
2y 1m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
89%
With Interview (+30.2%)
3y 9m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 712 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month